Educational Symposium - Friday May 15, 2009

Educational Symposium held prior to the ISPOR 14th Annual International Meeting

Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries

Friday, May 15, 2009
10:00AM – 5:00PM

Sponsored by Oxford Outcomes, National Pharmaceutical Council, and Shire

This symposium is free and open to all ISPOR delegates, no pre-registration required.

Over the past 50 years, major advances have been made in both the methods and application of health technology assessment (HTA). For example, the Cochrane Collaboration and Evidence-Based Medicine movement have provided systematized approaches of critically reviewing the scientific literature. More recently, new methods for making indirect comparisons are appearing in the literature which - when used judiciously - can be used to compare treatments in certain circumstances in which no head-to-head study has been conducted. Although the need for HTA was first explicitly conceptualized and implemented in the US in the 1960s and 1970s, many other countries followed suit. In many countries, for example Australia, Canada, Sweden, and the United Kingdom, rationalizing the use of new medical technologies was often the focus of many governmental and quasi-governmental health agencies.

Over recent years, the United States has witnessed renewed interest in HTA including calls, and proposed legislation, for developing a Centre for Comparative Effectiveness. However, there is still much debate on the essential elements of comparative effectiveness in the United States. That debate may benefit from the international experiences in HTA and the many countries which have well established agencies and processes for reviewing information on comparative effectiveness. Thought leaders presenting at this symposium will review recent trends in comparative effectiveness methodology and compare and contrast the experiences of countries that use formal HTA processes to review new medicines and technologies.

SYMPOSIUM SCHEDULE

10:00AM-10:15AM	WELCOME & OVERVIEW
	Moderator: Adrian Levy PhD, Associate Professor, University of British Columbia & Director, Oxford Outcomes, Vancouver, BC, Canada
10:15AM-10:35AM	COMPARATIVE EFFECTIVENESS IN THE UK
	Ron Akehurst BSc, Hon MFPHM, Professor of Health Economics. Dean and Chair of Executive Board, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
10:35AM-10:55AM	COMPARATIVE EFFECTIVENESS IN SWEDEN
	Egon Jonsson PhD, Executive Director and CEO, Institute of Health Economics, Alberta, Canada
10:55AM-11:15AM	COVERAGE WITH EVIDENCE DEVELOPMENT: THE ONTARIO EXPERIENCE
	Ron Goeree BA, MA, Associate Professor, Department of Clinical Epidemiology & Biostatistics, McMaster University & Director, Program for Assessment of Technology in Health, Hamilton, ON, Canada
11:15AM-11:30AM	BREAK

11:30AM-11:50AM	COMPARATIVE ASSESSMENT FOR MEDICATIONS AND DEVICES: APPLES AND ORANGES?
	Scott Ramsey MD, PhD, Professor, University of Washington, Member, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
11:50AM-12:15PM	LESSONS FOR THE USA
	Moderator: Lou Garrison AB, PhD, Professor, School of Pharmacy, University of Washington, Seattle, WA, USA
12:15PM-12:45PM	PANEL DISCUSSION – QUESTIONS/COMMENT All AM Speakers

12:45PM-1:15PM	LUNCH

1:15PM-1:25PM	OPENING REMARKS
	Moderator: Adrian Levy PhD, Associate Professor, University of British Columbia & Director, Oxford Outcomes, Vancouver, BC, Canada
1:25PM-1:45PM	CONTEMPORARY CHALLENGES IN DERIVING SUMMARY ESTIMATES OF COMPARATIVE EFFECTIVENESS USING META-ANALYSIS
	Ed Mills MSc, PhD, LLM, Research Scientist, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
1:45PM-2:05PM	NETWORK META-ANALYSIS: THE NEXT STEP FOR COMPARATIVE EFFECTIVENESS?
	Neil Hawkins PhD, MSc, Director, Oxford Outcomes, External Affiliate, York University, York, UK
2:05PM-2:25PM	REFLECTING HETEROGENEITY IN PATIENT BENEFITS: THE ROLE OF SUB-GROUP ANALYSIS WITH COMPARATIVE EFFECTIVENESS
	Mark Sculpher PhD Professor of Health Economics and Director of the Programme on Economic Evaluation and Health Technology Assessment, University of York, Centre for Health Economics, York, UK
2:25PM-2:45PM	TRANSPORTABILITY BETWEEN COUNTRIES OF ESTIMATES OF COMPARATIVE EFFECTIVENESS
	Andrew Briggs BA, MSc, DPhil, Lindsay Chair in Health Policy and Economic Evaluation, University of Glasgow, Glasgow, Scotland
2:45PM-3:05PM	EXPERIMENTAL AND OBSERVATIONAL DATA AND FORMULARY LISTING
	Raulo S. Frear PharmD, Director, Pharmacy Services, The Regence Group, Portland, Oregon, USA
3:05PM-3:25PM	NET CLINICAL BENEFIT: THE ART AND SCIENCE OF JOINTLY ESTIMATING BENEFITS AND RISKS OF MEDICAL TREATMENT
	Adrian Towse MA, MPhil, Director, Office of Health Economics, London, UK
3:25PM-3:45PM	LESSONS FOR THE USA
	Moderator: Lou Garrison AB, PhD, Professor, School of Pharmacy, University of Washington, Seattle, WA, USA
3:45PM-4:00PM	BREAK

4:00PM-4:45PM	DEBATE: PUBLICLY FUNDED ESTIMATES OF COMPARATIVE VALUE IN THE UNITED STATES SHOULD TAKE INTO CONSIDERATION ONLY NET CLINICAL BENEFIT AND EXPLICITLY EXCLUDE COST-EFFECTIVENESS
	Moderator: Seema Sonnad PhD, Director of Outcomes Research for the Department of Surgery, University of Pennsylvania Health System, Pennsylvania, PA, USA Pro: Kathy Buto BA, MPA, Vice President for Health Policy, Government Affairs, Johnson & Johnson, NJ, USA Con: Mark Helfand MD, MPH, Director, Oregon Evidence-based Practice Center, Portland, Oregon, USA
4:45PM-5:00PM	QUESTIONS & DISCUSSION All Speakers

5:00PM-5:30PM	RECEPTION